New agent offers image of liver lesions

July 10, 2008

This is the first organ-specific magnetic resonance imaging contrast agent approved in this country in more than a decade.

Liver lesions may be easier to detect now that the Food & Drug Administration has approved a new imaging agent. It's Bayer HealthCare Pharmaceuticals' Eovist (gadoxetate disodium) Injection, a gadolinium-based contrast agent, for intravenous use among patients with known or suspected focal liver disease. According to the Wayne, N.J., firm, Eovist is the first organ-specific magnetic resonance imaging contrast agent approved in this country in more than a decade.